Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neoplasms, Breast clinical trials
Every US clinical trial registered for Neoplasms, Breast — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.
10 US clinical trials ·
The research picture
Neoplasms, Breast has 10 registered US clinical trials; none are currently listed as recruiting, so most are completed or in follow-up.
- 0
- recruiting participants now
- 0%
- of trials open to enrollment
- 3
- in Phase 3–4 (later-stage)
- 6
- top sponsor: GlaxoSmithKline
Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.
Active & Recent Trials
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
GlaxoSmithKline
NCT04915755
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
Novartis Pharmaceuticals
NCT00490139
Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer
GlaxoSmithKline
NCT00075270
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
GlaxoSmithKline
NCT00347919
Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer
GlaxoSmithKline
NCT00089999
Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer
Emory University
NCT01271738
A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer
GlaxoSmithKline
NCT00058526
Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC
Novartis Pharmaceuticals
NCT00709761
Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)
GlaxoSmithKline
NCT00148902
Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.
Novartis Pharmaceuticals
NCT00367471
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
| Phase 3 | 3 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Neoplasms, Breast Trial Landscape
ClinicalTrials.gov lists 10 US studies indexed under Neoplasms, Breast, and 0 of those are currently open to recruitment — roughly 0% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Neoplasms, Breast shows 3 late-stage studies (Phase 3 and Phase 4 combined) alongside 6 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Neoplasms, Breast is led by GlaxoSmithKline with 6 indexed trials, alongside 2 other organizations in the top contributor list. The list on this page surfaces up to 10 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Neoplasms, Breast?
PlainTrial tracks 10 US clinical trials for Neoplasms, Breast, of which 0 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Neoplasms, Breast?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.